Single-Arm Trial of EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Head and Neck Carcinoma Metastatic/Refractory Nasopharyngeal Carcinoma
Latest Information Update: 25 Oct 2024
At a glance
- Drugs LMP2 specific TCR T cells-TCRCure Biotech (Primary)
- Indications Carcinoma; Head and neck cancer; Nasopharyngeal cancer
- Focus Adverse reactions
Most Recent Events
- 23 Oct 2024 Status changed from suspended to recruiting.
- 02 Oct 2024 Planned End Date changed from 1 Aug 2023 to 1 Dec 2024.
- 02 Oct 2024 Planned primary completion date changed from 1 Aug 2023 to 1 Dec 2024.